MedTrace Logo

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

NCT05477797 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2024-04-15

No results posted yet for this study

Summary

Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.

Conditions

  • Progression Free Survival
  • Overall Survival
  • Maintenance

Interventions

DRUG

Ixazomib DX/Lenalidomide DX

After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Lu Zhong · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-16
Primary Completion
2026-01-15
Completion
2026-01-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05477797 on ClinicalTrials.gov